G2 Goldfields Announces Graduation to the TSX
TORONTO, April 08, 2024 (GLOBE NEWSWIRE) — G2 Goldfields Inc. (“G2” or the “Company”) (TSXV:GTWO, OTCQX:GUYGF) is pleased to announce […]
Global Helium Corp. Announces Seismic Review Option Agreement With Industry Leader, North American Helium
CALGARY, Alberta, April 08, 2024 (GLOBE NEWSWIRE) — Global Helium Corp. (“HECO” or the “Company”) (CSE: HECO, OTC: HECOF) is […]
TSX News -
Ascot Commences Ore Processing at the Premier Gold Project
VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) — Ascot Resources Ltd. (TSX: AOT; OTCQX: AOTVF) (“Ascot” or the “Company”) […]
Macerich Schedules First Quarter 2024 Earnings Release and Conference Call
SANTA MONICA, Calif., April 08, 2024 (GLOBE NEWSWIRE) — WHAT: Macerich (NYSE: MAC) Schedules First Quarter 2024 Earnings Release and […]
IHT HOTEL REVENUE CONTINUES TO GROW
Phoenix, AZ, April 08, 2024 (GLOBE NEWSWIRE) — InnSuites Hospitality Trust (NYSE American: IHT) reported continued strong annual results in […]
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
MALVERN, Pa., April 08, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused […]
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
– Favorable safety and immunogenicity profile in ABCC6 Deficiency, with clinical improvements in vascular pathology, visual function and patient reported […]
TSX News -
K92 Mining Announces Imminent Resumption of Underground Operations
VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) — K92 Mining Inc. (“K92” or the “Company”) (TSX: KNT; OTCQB: KNTNF) announces that it […]
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
OCS-01 positive results in the first Phase 3 OPTIMIZE-1 trial were presented at the American Society of Cataract and Refractive […]
Ducommun Incorporated Confirms Receipt of Unsolicited, Non-Binding Indication of Interest From Albion River
SANTA ANA, Calif., April 08, 2024 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”), a global supplier […]
